NCT04064983

Brief Summary

This Individual Patient Expanded Access IND has been created as requested by an 58-year-old man who suffers from Polyneuropathy due to Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy, and Skin abnormalities (POEMS) Syndrome. The patient will receive 8 infusions of 200 million cells every four weeks during a 28-week period to relieve the symptoms of Polyneuropathy arising due to POEMS.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 19, 2019

Completed
3 days until next milestone

First Posted

Study publicly available on registry

August 22, 2019

Completed
Last Updated

September 29, 2025

Status Verified

September 1, 2025

First QC Date

August 19, 2019

Last Update Submit

September 24, 2025

Conditions

Polyneuropathies

Keywords

PolyneuoropathyPOEMSPainStem cellsNeuropathic Pain

Interventions

HB-adMSCsBIOLOGICAL

Hope Biosciences autologous adipose-derived mesenchymal stem cells

Eligibility Criteria

Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Patient diagnosed with Polyneuropathy due to POEMS Syndrome.
  • Patient must have banked his stem cells at Hope Biosciences LLC.

You may not qualify if:

  • The patient has any active infection requiring medications.
  • The patient has any suicidal ideation during the screening visit.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hope Biosciences Stem Cell Research Foundation

Sugar Land, Texas, 77478, United States

Location

MeSH Terms

Conditions

PolyneuropathiesPainNeuralgia

Condition Hierarchy (Ancestors)

Peripheral Nervous System DiseasesNeuromuscular DiseasesNervous System DiseasesNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Thanh Cheng, MD

    Hope Biosciences Stem Cell Research Foundation

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
expanded access
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 19, 2019

First Posted

August 22, 2019

Last Updated

September 29, 2025

Record last verified: 2025-09

Locations

US(1)